Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a promising U.S.-based epigenetics company with a novel Nucleosomics platform and strong focus on human diagnostics. The recent proof of concept data from a blinded validation cohort for the detection of early stage cancers using its Capture-Seq technology is highly encouraging, and if validated in larger cohorts, could potentially be used for Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) detection and treatment monitoring. The company is also in discussions with several leading diagnostic and liquid biopsy companies and may secure additional licensing deals in 2026, which could drive continued revenue growth.

Bears say

VolitionRX is a company that focuses on developing cost-effective blood tests for disease detection, including cancers and other life-altering conditions. While the company's Nucleosomics platform has shown potential in identifying and monitoring diseases, VolitionRX's financial risk and market share risk, coupled with the limited tools for risk stratification in the field, make the company's prospects uncertain. Additionally, while the recent Mayo Clinic study adds to the clinical validation of the platform, there is limited evidence of its effectiveness in real-world settings.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.